2009.06.04 Weekly Broadcast Email
The following updates were made to the website for the week of June 1, 2009.
The following adverse events were reported during the month of May. A PDF of the AE document has been attached to this email and a summary of the event can be found on the adverse event page of the website.
98308: AE 22-24
In the month of May, 8 patients were accrued to CCCWFU CCOP Research Base trials. Wake Forest was the top accruing site with 4 patients. See the Research Base website home page for accrual information on each site.
Featured Study: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients
Have you considered opening 91105 at your site? Has your site accrued patients to this study recently? You might be interested to know…
Several recent protocol changes have been made to study 91105, Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. These changes were made to facilitate and simplify enrollment which include:
-Adding a $40 gift for participating
-Simplifying and reducing medication exclusions
Visit the recently updated 91105 webpage to view:
• Upcoming conference call information
• Letter from the PI, Dr. Steve Rapp
• Brochure outlining recent changes
• Training video
97106 (Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors) only has 15 minority accrual slots open for patient accruals. We would like to see this study close by the end of the summer, so if you have patients that may be eligible for this study, please try and get them registered by then.